SCN1A

Sodium channel protein type 1 subunit alpha · P35498 · SCN1A on Sugi Atlas →

104,814 patent compounds predicted against SCN1A, 65,930 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Ambucaine (SCHEMBL82280)	0.91	8/20
Metabutoxycaine (SCHEMBL25778)	0.58	7/20
Propoxycaine (SCHEMBL83073)	1.00	6/20
Propoxycaine (SCHEMBL24720)	0.98	6/20
Biphenamine (SCHEMBL25980)	0.81	6/20
Chloroprocaine (SCHEMBL6676)	0.67	6/20
SCHEMBL121564	0.39	6/20
Benoxinate (SCHEMBL25087)	1.00	5/20
Betoxycaine (SCHEMBL25758)	0.77	5/20
Procaine (SCHEMBL3524)	0.68	5/20
Chloroprocaine (SCHEMBL24096)	0.66	5/20
SCHEMBL517	0.40	5/20
Proparacaine (SCHEMBL23334)	1.00	4/20
SCHEMBL25906	1.00	4/20
SCHEMBL25907	1.00	4/20
Parethoxycaine (SCHEMBL25944)	1.00	4/20
Proparacaine (SCHEMBL23333)	0.98	4/20
Proparacaine (SCHEMBL93880)	0.98	4/20
SCHEMBL25553	0.81	4/20
Hydroquinine (SCHEMBL109600)	0.81	4/20

Clinical trials — most relevant to SCN1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations	PHASE4	COMPLETED
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age	PHASE4	RECRUITING
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome	PHASE3	RECRUITING
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety	PHASE3	RECRUITING
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)	PHASE3	RECRUITING
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome	PHASE2	COMPLETED
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome	PHASE1/PHASE2	RECRUITING
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies	PHASE2	WITHDRAWN
A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
Treatment of Gait Disorders in Children With Dravet Syndrome	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
Cardiac Arrhythmias in Dravet Syndrome	nan	COMPLETED
GABA Biomarkers in Dravet Syndrome	nan	RECRUITING
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age	nan	RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Drug Resistant Epilepsy: Clinical and Genetic Study	nan	UNKNOWN
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Impact on Risk Stratification of Overlap Syndrome Phenotype in Patients With E1784K Mutation in SCN5A	nan	COMPLETED
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome	nan	UNKNOWN
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome	nan	ACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SCN1A binder may also engage these)

Protein	Name	Similarity
A2APX8	—	1.000	A2APX8 →
SCN2A	Sodium channel protein type 2 subunit alpha	1.000	landscape →
P04774	—	1.000	P04774 →
SCN3A	Sodium channel protein type 3 subunit alpha	1.000	landscape →
P04775	—	1.000	P04775 →
Q28644	—	1.000	Q28644 →
O08562	—	1.000	O08562 →
Q62205	—	1.000	Q62205 →
B1AWN6	—	1.000	B1AWN6 →
O88420	—	1.000	O88420 →
P08104	—	1.000	P08104 →
SCN9A	Sodium channel protein type 9 subunit alpha	1.000	landscape →
A2ASI5	—	1.000	A2ASI5 →
SCN8A	Sodium channel protein type 8 subunit alpha	0.999	landscape →
Q9WTU3	—	0.998	Q9WTU3 →
P15390	—	0.997	P15390 →
Q2XVR7	—	0.996	Q2XVR7 →
Q2XVR3	—	0.996	Q2XVR3 →
P02719	—	0.996	P02719 →
Q62968	—	0.995	Q62968 →
P15389	—	0.995	P15389 →
Q6QIY3	—	0.995	Q6QIY3 →
P35500	—	0.994	P35500 →
Q20JQ7	—	0.994	Q20JQ7 →
Q9JJV9	—	0.994	Q9JJV9 →
Q9W0Y8	—	0.994	Q9W0Y8 →
Q2XVR6	—	0.993	Q2XVR6 →
SCN10A	Sodium channel protein type 10 subunit alpha	0.992	landscape →
Q28371	—	0.992	Q28371 →
Q9ER60	—	0.992	Q9ER60 →